- 生物共軛 -
Antibody-Drug Conjugates Come of Age
The field of ADCs has experienced its fair share of ups-and-downs on the road to clinic and regulatory approvals. Finally, this year we saw the approval of POLIVY™, with several promising ADCs drumming up the excitement in the coming months. To highlight the dynamic landscape, CHI’s Bioconjugates Stream will present a 2-part Antibody-Drug Conjugates program:
Part 1: Engineering Antibody-Drug Conjugates invites scientists to discuss novel design strategies to engineer the right ADC combinations, using novel payloads, new non-IgG platforms, and/or creative linker/conjugation technologies.
Part 2: Clinical Progress of Antibody-Drug Conjugates invites investigators to share their latest results from preclinical to clinical trials, lessons learned from past ADC programs and related fields to inform next-gen ADC design, and to develop better predictability for translation from bench to clinic.
Rakesh Dixit, DAPT PhD, President & CEO, Bionavigen
Greg Thurber, PhD Associate Professor, Chemical Engineering and Biomedical Engineering, University of Michigan